Payment overview · 2025
General Payments
$2,521.27
115 reported records · 13 companies
Healthcare provider profile · identity verified
Wingtat Mui, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1497837090
Verified facts
What the public records show
CMS Open Payments records show Wingtat Mui, M.D. received $2,521.27 in general payments during 2025 across 115 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus, Shingrix, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synjardy by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexlizet by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $563.82 | 22.4% | 26 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $555.67 | 22.0% | 19 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $441.94 | 17.5% | 25 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $225.01 | 8.9% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $185.97 | 7.4% | 8 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $175.97 | 7.0% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $93.04 | 3.7% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $86.63 | 3.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.64 | 2.5% | 3 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $50.73 | 2.0% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $29.16 | 1.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.54 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.15 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,515.72 | 114 |
| Education | $5.55 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $399.04 | 23 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $264.92 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $225.01 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $225.01 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $202.81 | 10 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $175.97 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $104.48 | 5 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $86.63 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $64.65 | 3 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $50.73 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.61 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $42.70 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $29.16 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $28.39 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.39 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $26.54 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $26.54 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $26.32 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $14.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 62 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 209 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 211 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 319 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 46 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 74 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 180 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 113 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
104 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
180 | 28 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
70 | 49 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
211 | 53 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
253 | 41 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
61 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
319 | 57 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
201 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
74 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
113 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
209 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1949 | 393 |
| Losartan Potassium | Losartan Potassium | 1541 | 328 |
| Amlodipine Besylate | Amlodipine Besylate | 1513 | 298 |
| Vascepa | Icosapent Ethyl | 1333 | 256 |
| Omeprazole | Omeprazole | 899 | 237 |
| Simvastatin | Simvastatin | 854 | 157 |
| Metoprolol Succinate | Metoprolol Succinate | 796 | 164 |
| Diclofenac Epolamine | Diclofenac Epolamine | 763 | 169 |
| Metformin Hcl | Metformin Hcl | 734 | 141 |
| Donepezil Hcl | Donepezil Hcl | 725 | 133 |
| Tamsulosin Hcl | Tamsulosin Hcl | 705 | 154 |
| Raloxifene Hcl | Raloxifene Hcl | 659 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 508 | 107 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 479 | 96 |
| Gabapentin | Gabapentin | 454 | 113 |
| Trazodone Hcl | Trazodone Hcl | 436 | 121 |
| Metformin Hcl Er | Metformin Hcl | 423 | 91 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 422 | 102 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 397 | 91 |
| Montelukast Sodium | Montelukast Sodium | 397 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 344 | 89 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 344 | 144 |
| Meloxicam | Meloxicam | 337 | 144 |
| Finasteride | Finasteride | 336 | 74 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 327 | 79 |
| Halobetasol Propionate | Halobetasol Propionate | 320 | 97 |
| Jardiance | Empagliflozin | 319 | 57 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 315 | 61 |
| Alendronate Sodium | Alendronate Sodium | 309 | 59 |
| Famotidine | Famotidine | 294 | 76 |
| Meclizine Hcl | Meclizine Hcl | 287 | 166 |
| Levothyroxine Sodium | Levothyroxine Sodium | 284 | 66 |
| Fluticasone Propionate | Fluticasone Propionate | 279 | 113 |
| Allopurinol | Allopurinol | 278 | 55 |
| Ammonium Lactate | Ammonium Lactate | 264 | 117 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 256 | 61 |
| Nexium | Esomeprazole Magnesium | 253 | 41 |
| Bepotastine Besilate | Bepotastine Besilate | 250 | 83 |
| Azithromycin | Azithromycin | 248 | 202 |
| Pioglitazone Hcl | Pioglitazone Hcl | 235 | 49 |
| Celecoxib | Celecoxib | 233 | 79 |
| Mometasone Furoate | Mometasone Furoate | 224 | 73 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 215 | 57 |
| Farxiga | Dapagliflozin Propanediol | 211 | 53 |
| Eliquis | Apixaban | 209 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 207 | 45 |
| Glipizide Er | Glipizide | 205 | 45 |
| Dexlansoprazole Dr | Dexlansoprazole | 201 | 46 |
| Vemlidy | Tenofovir Alafenamide | 201 | 25 |
| Lisinopril | Lisinopril | 197 | 32 |
| Atenolol | Atenolol | 192 | 30 |
| Clobetasol Propionate | Clobetasol Propionate | 190 | 59 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 181 | 49 |
| Januvia | Sitagliptin Phosphate | 180 | 31 |
| Synthroid | Levothyroxine Sodium | 180 | 28 |
| Myrbetriq | Mirabegron | 179 | 35 |
| Baclofen | Baclofen | 175 | 52 |
| Carvedilol | Carvedilol | 175 | 31 |
| Mupirocin | Mupirocin | 172 | 80 |
| Lidocaine | Lidocaine | 170 | 63 |
| Azelastine Hcl | Azelastine Hcl | 161 | 66 |
| Ezetimibe | Ezetimibe | 161 | 29 |
| Spironolactone | Spironolactone | 158 | 33 |
| Procto-Med Hc | Hydrocortisone | 149 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 148 | 61 |
| Hydralazine Hcl | Hydralazine Hcl | 148 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 148 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 143 | 36 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 142 | 27 |
| Hydrocortisone | Hydrocortisone | 142 | 48 |
| Sertraline Hcl | Sertraline Hcl | 137 | 31 |
| Mirtazapine | Mirtazapine | 129 | 25 |
| Naproxen | Naproxen | 129 | 65 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 129 | 23 |
| Memantine Hcl | Memantine Hcl | 124 | 22 |
| Restasis | Cyclosporine | 123 | 32 |
| Amoxicillin | Amoxicillin | 122 | 98 |
| Loperamide | Loperamide Hcl | 121 | 66 |
| Acarbose | Acarbose | 117 | 23 |
| Xarelto | Rivaroxaban | 116 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 26 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 109 | 45 |
| Fenofibrate | Fenofibrate,micronized | 107 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 25 |
| Linzess | Linaclotide | 104 | 22 |
| Tradjenta | Linagliptin | 103 | 26 |
| Ketoconazole | Ketoconazole | 101 | 39 |
| Telmisartan | Telmisartan | 101 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 22 |
| Colchicine | Colchicine | 93 | 28 |
| Ibuprofen | Ibuprofen | 93 | 72 |
| Potassium Chloride | Potassium Chloride | 93 | 17 |
| Furosemide | Furosemide | 91 | 25 |
| Glimepiride | Glimepiride | 91 | 16 |
| Pregabalin | Pregabalin | 88 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 84 | 31 |
| Prednisone | Prednisone | 79 | 61 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | 15 |
| Chlorthalidone | Chlorthalidone | 74 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 74 | 49 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 71 | 15 |
| Prolia | Denosumab | 70 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 68 | 12 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 68 | 40 |
| Ranolazine Er | Ranolazine | 64 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 63 | 32 |
| Dutasteride | Dutasteride | 63 | suppressed |
| Creon | Lipase/Protease/Amylase | 62 | 15 |
| Nifedipine Er | Nifedipine | 62 | 11 |
| Valsartan | Valsartan | 62 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 61 | 11 |
| Labetalol Hcl | Labetalol Hcl | 61 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 61 | 19 |
| Torsemide | Torsemide | 60 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 59 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 59 | 14 |
| Ozempic | Semaglutide | 56 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 55 | 31 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 55 | 12 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 54 | 21 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 53 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 52 | 15 |
| Entecavir | Entecavir | 51 | suppressed |
| Folic Acid | Folic Acid | 51 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 50 | 11 |
| Clonazepam | Clonazepam | 49 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 49 | suppressed |
| Methimazole | Methimazole | 48 | suppressed |
| Fenofibrate | Fenofibrate | 47 | suppressed |
| Edarbi | Azilsartan Medoxomil | 46 | suppressed |
| Rybelsus | Semaglutide | 46 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 45 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 28 |
| Enalapril Maleate | Enalapril Maleate | 41 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 40 | suppressed |
| Fluocinonide | Fluocinonide | 40 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 32 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 38 | 13 |
| Irbesartan | Irbesartan | 37 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Brilinta | Ticagrelor | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 29 |
| Olanzapine | Olanzapine | 34 | suppressed |
| Ciclopirox | Ciclopirox | 33 | suppressed |
| Glipizide | Glipizide | 33 | suppressed |
| Livalo | Pitavastatin Calcium | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 29 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 32 | 16 |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 31 | suppressed |
| Erythromycin | Erythromycin Base | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | 19 |
| Dexilant | Dexlansoprazole | 30 | 13 |
| Propylthiouracil | Propylthiouracil | 30 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | 11 |
| Megestrol Acetate | Megestrol Acetate | 28 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 23 |
| Tacrolimus | Tacrolimus | 25 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 24 | suppressed |
| Clotrimazole | Clotrimazole | 24 | 11 |
| Nitroglycerin | Nitroglycerin | 24 | 17 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 24 | 11 |
| Calcitriol | Calcitriol | 23 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Benicar | Olmesartan Medoxomil | 21 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 19 | suppressed |
| Proctozone-Hc | Hydrocortisone | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 19 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 18 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Clemastine Fumarate | Clemastine Fumarate | 18 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 18 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Repaglinide | Repaglinide | 18 | suppressed |
| Scopolamine | Scopolamine | 18 | 13 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Cyclosporine | Cyclosporine | 16 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Terconazole | Terconazole | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Avodart | Dutasteride | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Crestor | Rosuvastatin Calcium | 15 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 11 |
| Mitigare | Colchicine | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Vesicare | Solifenacin Succinate | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Saxagliptin-Metformin Er | Saxagliptin Hcl/Metformin Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 11 | suppressed |
| Mupirocin | Mupirocin Calcium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,521.27 · 115 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APRETUDE, BEXSERO, BREZTRI, CAPVAXIVE, CREON, ELIQUIS, EVENITY, FARXIGA, Fluad, Flucelvax, GARDASIL 9, JARDIANCE, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PENMENVY, QULIPTA, REPATHA, Rybelsus, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, ZORYVE | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error